Device Trial Radar · NCT06052956
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 15, 2027
Primary completion
Jun 30, 2032
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- University of RochesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous abscess drainage for disinfection of deep tissue abscesses. The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage , (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage , and (3) sham control + standard of care abscess drainage. The primary endpoint is time to removal of the drainage catheter.
Conditions
- Abscess
Interventions
Methylene BlueDrug
Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
Lipid EmulsionDrug
The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
Insertion of optical fiberDevice
A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
Laser Illumination (pre-defined dose)Device
Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
Optical Spectroscopy MeasurementDevice
The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
Laser Illumination (patient-specific dose)Device
Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
Standard of care abscess drainageProcedure
Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
Inert blue dyeDrug
Administration of inert, sterile, clinical-grade blue dye to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with clear, sterile saline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to removal of the drainage catheterTime frame: Day 1 post-intervention until removal of drainage catheter
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Highland Hospital
Rochester, New York
University of Rochester Medical Center
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.